PureTech Health to Present Promising IPF Trial Results at ATS Conference

PureTech Health ( (GB:PRTC) ) has provided an update.

PureTech Health announced that it will present results from its Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100) at the American Thoracic Society International Conference. The trial demonstrated significant efficacy in stabilizing lung function decline in idiopathic pulmonary fibrosis (IPF) patients over 26 weeks, suggesting deupirfenidone could become a new standard of care. The company plans to meet with the FDA to discuss a potential Phase 3 trial by the end of 2025, aiming to provide a transformative treatment option for IPF patients.

More about PureTech Health

PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to address devastating diseases. The company has a diverse portfolio of 29 therapeutics and therapeutic candidates, including three FDA-approved treatments, advanced through its research and development efforts and collaborations with scientists and industry leaders.

YTD Price Performance: -18.11%

Average Trading Volume: 630,452

Technical Sentiment Signal: Buy

Current Market Cap: £295.4M

See more data about PRTC stock on TipRanks’ Stock Analysis page.